Interactive Investor
>>

Antibe Therapeutics Inc (TSE:ATE) Share Price

ATE

Antibe Therapeutics Inc

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Medical Devices

 / 

- / -
-
- / -
-
-
-

NAV Price

-

Last Traded

-

Chg

-

-

XTSE

-

Updated: -

Loading...

Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.Antibe Therapeutics Inc is a healthcare company. It is engaged in the development of patents and out-licensing of improved compounds of existing drugs. The company has two primary business segments: Antibe Therapeutics and Citagenix.

TSE:ATE

CA0370255097

CAD

Loading...

Loading Comparison

Latest ATE News

Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News